We are live on ! Find out more
RI

RTW Investments Portfolio holdings

AUM $10B
1-Year Est. Return 135.35%
This Fund
S&P 500
This Quarter Est. Return
-16.57%
1 Year Est. Return
+135.35%
3 Year Est. Return
+383.62%
5 Year Est. Return
+523.94%
10 Year Est. Return
+15,981.64%
AUM
$2.32B
AUM Growth
-$327M
Cap. Flow
+$342M
Cap. Flow %
14.73%
Top 10 Hldgs %
50.61%
Holding
68
New
7
Increased
38
Reduced
3
Closed
3

Top Buys

Rank Stock Value
1
GBT
Global Blood Therapeutics, Inc.
GBT
+$48.2M
2
ZBH icon
Zimmer Biomet
ZBH
+$31.6M
3
OYST
Oyster Point Pharma, Inc. Common Stock
OYST
+$31.4M
4
TNDM icon
Tandem Diabetes Care
TNDM
+$31.1M
5
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$30.5M

Top Sells

Rank Stock Value
1
ACHN
Achillion Pharmaceuticals
ACHN
+$44.1M
2
ARVN icon
Arvinas
ARVN
+$15.2M
3
A icon
Agilent Technologies
A
+$12.8M
4
PODD icon
Insulet
PODD
+$11.6M
5
SRPT icon
Sarepta Therapeutics
SRPT
+$8.74M

Sector Composition

Rank Sector Weight
1 Healthcare 94.12%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RCKT icon
1
Rocket Pharmaceuticals
RCKT
$355M
$235M 10.1%
16,812,491
– –
ALNY icon
2
Alnylam Pharmaceuticals
ALNY
$37.2B
$183M 7.88%
1,681,645
+43,781
+3% +$5.05M
PTCT icon
3
PTC Therapeutics
PTCT
$6.29B
$175M 7.55%
3,932,746
+100,266
+3% +$5.05M
DRNA
4
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
$128M 5.51%
6,963,135
+1,088,906
+19% +$21.2M
BMY icon
5
Bristol-Myers Squibb
BMY
$128B
$94M 4.05%
1,685,934
+42,983
+3% +$2.63M
STOK icon
6
Stoke Therapeutics
STOK
$1.83B
$81.2M 3.49%
3,544,248
– –
MRTX
7
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$75.7M 3.26%
985,166
+339,739
+53% +$30.5M
QTTB icon
8
Q32 Bio
QTTB
$452M
$68.4M 2.94%
244,403
+2,778
+1% +$851K
ZBH icon
9
Zimmer Biomet
ZBH
$17.8B
$67.9M 2.92%
691,601
+241,094
+54% +$31.6M
MASI
10
DELISTED
Masimo
MASI
$67.8M 2.92%
382,915
+728
+0.2% +$125K
IMVT icon
11
Immunovant
IMVT
$8.23B
$65.9M 2.84%
4,426,106
– –
ADVM
12
DELISTED
Adverum Biotechnologies
ADVM
$64.8M 2.79%
663,163
+24,502
+4% +$2.86M
AXSM icon
13
Axsome Therapeutics
AXSM
$12.3B
$61.9M 2.67%
1,052,969
+26,156
+3% +$2.13M
BLU
14
DELISTED
BELLUS Health Inc.
BLU
$54.7M 2.36%
5,490,992
+650,000
+13% +$5.79M
SRPT icon
15
Sarepta Therapeutics
SRPT
$1.68B
$51.8M 2.23%
529,261
-76,501
-13% -$8.74M
AXNX
16
DELISTED
Axonics, Inc. Common Stock
AXNX
$43.4M 1.87%
1,709,000
+117,368
+7% +$3.49M
VCEL icon
17
Vericel Corp
VCEL
$2.31B
$40.9M 1.76%
4,460,755
+1,471,326
+49% +$22.1M
NTRA icon
18
Natera
NTRA
$37B
$37.8M 1.63%
1,266,125
+863,172
+214% +$28.8M
KRRO icon
19
Korro Bio
KRRO
$155M
$36.9M 1.59%
41,424
+15,367
+59% +$16.6M
TBIO
20
DELISTED
Translate Bio, Inc. Common Stock
TBIO
$36.8M 1.58%
3,692,424
+387,616
+12% +$3.18M
GBT
21
DELISTED
Global Blood Therapeutics, Inc.
GBT
$36.8M 1.58%
+719,489
New +$48.2M
MYOK
22
DELISTED
MyoKardia, Inc. Common Stock
MYOK
$36.6M 1.58%
780,898
+19,910
+3% +$1.28M
AVDL
23
DELISTED
Avadel Pharmaceuticals
AVDL
$36.3M 1.56%
4,616,570
+1,215,136
+36% +$9.33M
OYST
24
DELISTED
Oyster Point Pharma, Inc. Common Stock
OYST
$33.9M 1.46%
+969,478
New +$31.4M
RLMD icon
25
Relmada Therapeutics
RLMD
$546M
$33.6M 1.45%
984,542
+320,058
+48% +$12.9M
1
2 3

Similar funds

LWCFA
Loring Wolcott & Coolidge Fiduciary Advisors Boston, Massachusetts $9.98B AUM 4.97% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $9.98B AUM 145.42% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
OAM
OP Asset Management Helsinki $9.95B AUM 30.22% 1-Year Est. Return
GI
GAMCO Investors Greenwich, Connecticut $10.2B AUM 30.27% 1-Year Est. Return
IIM
INTECH Investment Management West Palm Beach, Florida $10.2B AUM 28.14% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
FPAS
Focus Partners Advisor Solutions Saint Louis, Missouri $9.92B AUM 21.52% 1-Year Est. Return

RTW Investments's Q1 2020 Portfolio in Review

As of Q1 2020, RTW Investments held 68 positions worth $2.32B, down 12% from $2.65B the previous quarter. Its ten largest holdings account for 51% of the portfolio.

RTW Investments deployed $342M of net new capital in Q1 2020, opening 7 new positions and adding to 38 existing holdings. Its largest new stake was Global Blood Therapeutics, Inc.: 719,489 shares worth $36.8M.

By sector, the portfolio is most concentrated in Healthcare at 94% of assets, down from 95% a quarter earlier.

On the sell side, the largest reduction was Arvinas, an estimated $15.2M trimmed.

  • RTW Investments's largest Q1 2020 buy was Global Blood Therapeutics, Inc.: 719,489 shares worth $36.8M.
  • RTW Investments added most to Zimmer Biomet in Q1 2020, an estimated $31.6M increase.
  • RTW Investments's biggest Q1 2020 reduction was Arvinas, cutting an estimated $15.2M.
  • RTW Investments fully exited Achillion Pharmaceuticals in Q1 2020, selling an estimated $44.1M.
  • RTW Investments's ten largest holdings make up 51% of its $2.32B portfolio in Q1 2020.
  • RTW Investments opened 7 new positions and closed 3 in Q1 2020.
  • RTW Investments's portfolio value fell 12% quarter-over-quarter to $2.32B.

Based on RTW Investments's 13F filing for Q1 2020, filed 15 May 2020.